Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients
| Główni autorzy: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Wydane: |
2012
|
| _version_ | 1826296553230303232 |
|---|---|
| author | Gold, R Kappos, L Palace, J Siever, A Marrosu, M Gottschalk, R Bijarnia, M Keil, A Tomic, D von Rosenstiel, P Comi, G |
| author_facet | Gold, R Kappos, L Palace, J Siever, A Marrosu, M Gottschalk, R Bijarnia, M Keil, A Tomic, D von Rosenstiel, P Comi, G |
| author_sort | Gold, R |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T04:18:07Z |
| format | Conference item |
| id | oxford-uuid:ca1645fa-5ae6-4e2f-8271-2a8fb11a74df |
| institution | University of Oxford |
| last_indexed | 2024-03-07T04:18:07Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:ca1645fa-5ae6-4e2f-8271-2a8fb11a74df2022-03-27T07:04:50ZCardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patientsConference itemhttp://purl.org/coar/resource_type/c_5794uuid:ca1645fa-5ae6-4e2f-8271-2a8fb11a74dfSymplectic Elements at Oxford2012Gold, RKappos, LPalace, JSiever, AMarrosu, MGottschalk, RBijarnia, MKeil, ATomic, Dvon Rosenstiel, PComi, G |
| spellingShingle | Gold, R Kappos, L Palace, J Siever, A Marrosu, M Gottschalk, R Bijarnia, M Keil, A Tomic, D von Rosenstiel, P Comi, G Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title | Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title_full | Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title_fullStr | Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title_full_unstemmed | Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title_short | Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients |
| title_sort | cardiac safety of fingolimod 0 5 mg during the first dose observation in a 4 month open label multicentre first study in relapsing multiple sclerosis patients |
| work_keys_str_mv | AT goldr cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT kapposl cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT palacej cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT sievera cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT marrosum cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT gottschalkr cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT bijarniam cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT keila cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT tomicd cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT vonrosenstielp cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients AT comig cardiacsafetyoffingolimod05mgduringthefirstdoseobservationina4monthopenlabelmulticentrefirststudyinrelapsingmultiplesclerosispatients |